Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / COM
-
Number of holders
-
36
-
Total 13F shares, excl. options
-
8,821,889
-
Shares change
-
+4,732,186
-
Total reported value, excl. options
-
$39,349,366
-
Value change
-
+$21,195,496
-
Put/Call ratio
-
1.33%
-
Number of buys
-
26
-
Number of sells
-
-7
-
Price
-
$4.46
Significant Holders of Protalix BioTherapeutics, Inc. - COM (PLX) as of Q1 2021
48 filings reported holding PLX - Protalix BioTherapeutics, Inc. - COM as of Q1 2021.
Protalix BioTherapeutics, Inc. - COM (PLX) has 36 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 8,821,889 shares
.
Largest 10 shareholders include Psagot Investment House Ltd. (3,095,741 shares), Burrage Capital Management LLC (2,125,585 shares), DAFNA Capital Management LLC (1,204,825 shares), RENAISSANCE TECHNOLOGIES LLC (507,634 shares), UBS OCONNOR LLC (445,171 shares), BRIDGEWAY CAPITAL MANAGEMENT, LLC (302,591 shares), Phoenix Holdings Ltd. (244,113 shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (203,813 shares), D.A. DAVIDSON & CO. (130,700 shares), and ADVISOR GROUP HOLDINGS, INC. (122,184 shares).
This table shows the top 36 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.